Comparative Pharmacology
Head-to-head clinical analysis: IOMERVU versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOMERVU versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
IOMERVU vs IOPAMIDOL-200 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by increasing radiopacity of blood vessels and tissues, allowing visualization during imaging procedures.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Intravenous: 0.5-2 mL/kg of iomeprol 300-400 mg I/mL for imaging, not exceeding 200 mL total dose; arterial: up to 250 mL per procedure.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 10-30 hours in severe impairment), necessitating dose adjustment and monitoring. The half-life is not significantly affected by hepatic impairment.
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Iomeprol is almost exclusively eliminated via renal glomerular filtration, with 92-98% of the administered dose recovered unchanged in urine within 24 hours. Less than 2% is excreted in feces via biliary elimination. In patients with normal renal function, renal clearance approximates glomerular filtration rate.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent